New mechanisms of hypertension in chronic kidney disease

doi:10.3877/cma.j.issn.2095-3216.2020.01.007

Abstract

Abstract:

Hypertension is not only involved in the etiology of CKD, but also an important risk factor for both the progression of CKD and the cardiovascular and cerebrovascular events. In addition to the classic pathogenesis of hypertension in CKD, new mechanisms have also been found in recent years, including immune factors, microRNAs, increase of the sympathetic nervous system activity in cerebrospinal fluid, disorder of cutaneous lymphatic reflux, and intervention of PPAR-γ signals in vascular smooth muscle cells leading to autonomic dysfunction. These new mechanisms were reviewed in this article.

Key words: Chronic kidney disease, Hypertension

Jin Feng, Aihua Zhang. New mechanisms of hypertension in chronic kidney disease[J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2020, 09(01): 33-37.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhsbyjdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-3216.2020.01.007

https://zhsbyjdzzz.cma-cmc.com.cn/EN/Y2020/V09/I01/33

References 46

[1]	Zhang L, Wang F, Wang L, et al. Prevalence of chronic kidney disease in China: a cross-sectional survey [J]. Lancet, 2012, 379 (9818): 815-822.
[2]	Zheng Y, Cai GY, Chen XM, et al. Prevalence, awareness, treatment, and control of hypertension in the non-dialysis chronic kidney disease patients [J]. Chin Med J (Engl), 2013, 126(12): 2276-2280.
[3]	Haddy FJ. Role of dietary salt in hypertension [J]. Life Sci, 2006, 79(17): 1585-1592.
[4]	Tornel J, Madrid MI, Garcia-Salom M, et al. Role of kinins in the control of renal papillary blood flow, pressure natriuresis, and arterial pressure [J]. Circ Res, 2000, 86(5): 589-595.
[5]	Majima M, Hayashi I, Fujita T, et al. Facilitation of renal kallikrein-kinin system prevents the development of hypertension by inhibition of sodium retention [J]. Immunopharmacology, 1999, 44(1-2): 145-152.
[6]	Zoccali C, Mallamaci F, Tripepi G. Novel cardiovascular risk factors in end-stage renal disease [J]. J Am Soc Nephrol, 2004, 15(Suppl 1): S77-S80.
[7]	Schroder M, Riedel E, Beck W, et al. Increased reduction of dimethylarginines and lowered interdialytic blood pressure by the use of biocompatible membranes [J]. Kidney Int Suppl, 2001, 78: S19-S24.
[8]	Kielstein JT, Boger RH, Bode-Boger SM, et al. Asymmetric dimethylarginine plasma concentrations differ in patients with end-stage renal disease: relationship to treatment method and atherosclerotic disease [J]. J Am Soc Nephrol, 1999, 10(3): 594-600.
[9]	Goldblatt H, Lynch J, Hanzal RF, et al. Studies on experimental hypertension: I. the production of persistent elevation of systolic blood pressure by means of renal ischemia [J]. J Exp Med, 1934, 59 (3): 347-379.
[10]	Godlewski G, Alapafuja SO, Batkai S, et al. Inhibitor of fatty acid amide hydrolase normalizes cardiovascular function in hypertension without adverse metabolic effects [J]. Chem Biol, 2010, 17(11): 1256-1266.
[11]	Guo Z, Liu YX, Yuan F, et al. Enhanced vasorelaxation effect of endogenous anandamide on thoracic aorta in renal vascular hypertension rats [J]. Clin Exp Pharmacol Physiol, 2015, 42(9): 950-955.
[12]	Wang Y, Wang DH. A novel mechanism contributing to development of Dahl salt-sensitive hypertension: role of the transient receptor potential vanilloid type 1 [J]. Hypertension, 2006, 47(3): 609-614.
[13]	Bai Q, Zhang J, Zhang AH, et al. Role of arachidonoylethanolamine in blood pressure regulation in volume-resistant patients on peritoneal dialysis [J]. Int Urol Nephrol, 2012, 44(6): 1855-1860.
[14]	Zhu L, Sui L, Wu S, et al. Association between essential hypertension and three vasoactive peptides, urotensin Ⅱ，endothelin and adrenomedullin [J]. Clin Exp Hypertens, 2015, 37 (7): 604-608.
[15]	Şatıroĝu Ö, Durakoĝlugil ME, Cetin M, et al. The role of urotensin Ⅱ and atherosclerotic risk factors in patients with slow coronary flow [J]. Interv Med Appl Sci, 2016, 8(4): 158-163.
[16]	Lin Y, Tsuchihashi T, Matsumura K, et al. Central cardiovascular action of urotensin Ⅱ in spontaneously hypertensive rats [J]. Hypertens Res, 2003, 26(10): 839-845.
[17]	He WY, Bai Q, A LT, et al. Irisin levels are associated with urotensin Ⅱ levels in diabetic patients [J]. J Diabetes Investig, 2015, 6(5): 571-576.
[18]	McMaster WG, Kirabo A, Madhur MS, et al. Inflammation, immunity, and hypertensive end-organ damage [J]. Circ Res, 2015, 116(6): 1022-1033.
[19]	Sakaguchi M, Kato H, Nishiyori A, et al. Characterization of CD4^＋ T helper cells in patients with Kawasaki disease (KD): preferential production of tumour necrosis factor-alpha (TNF-alpha) by V beta 2- or V beta 8- CD4^＋ T helper cells [J]. Clin Exp Immunol, 1995, 99(2): 276-282.
[20]	Peleli M, Flacker P, Zhuge Z, et al. Renal denervation attenuates hypertension and renal dysfunction in a model of cardiovascular and renal disease, which is associated with reduced NADPH and xanthine oxidase activity [J]. Redox Biol, 2017, 13: 522-527.
[21]	Fabbiano S, Menacho-Márquez M, Robles-Valero J, et al. Immunosuppression-independent role of regulatory T cells against hypertension-driven renal dysfunctions [J]. Mol Cell Biol, 2015, 35(20): 3528-3546.
[22]	Davies SS, Amarnath V, Roberts LJ 2nd. Isoketals: highly reactive gamma-ketoaldehydes formed from the H2-isoprostane pathway [J]. Chem Phys Lipids, 2004, 128(1-2): 85-99.
[23]	Roychowdhury S, McMullen MR, Pritchard MT, et al. Formation of gamma-ketoaldehyde-protein adducts during ethanol-induced liver injury in mice [J]. Free Radic Biol Med, 2009, 47(11): 1526-1538.
[24]	Kirabo A, Fontana V, de Faria AP, et al. DC isoketal-modified proteins activate T cells and promote hypertension [J]. J Clin Invest, 2014, 124(10): 4642-4656.
[25]	Peleli M, Al-Mashhadi A, Yang T, et al. Renal denervation attenuates NADPH oxidase-mediated oxidative stress and hypertension in rats with hydronephrosis [J]. Am J Physiol Renal Physiol, 2016, 310(1): F43-F56.
[26]	Rafiq A, Aslam K, Malik R, et al. C242T polymorphism of the NADPH oxidase p22PHOX gene and its association with endothelial dysfunction in asymptomatic individuals with essential systemic hypertension [J]. Mol Med Rep, 2014, 9(5): 1857-1862.
[27]	Gray SP, Jandeleit-Dahm KA. The role of NADPH oxidase in vascular disease--hypertension, atherosclerosis & stroke [J]. Curr Pharm Des, 2015, 21(41): 5933-5944.
[28]	Qiu Y, Tao L, Lei C, et al. Downregulating p22phox ameliorates inflammatory response in Angiotensin Ⅱ-induced oxidative stress by regulating MAPK and NF-kappaB pathways in ARPE-19 cells [J]. Sci Rep, 2015, 5: 14362.
[29]	Sun Y, Koo S, White N, et al. Development of a micro-array to detect human and mouse microRNAs and characterization of expression in human organs [J]. Nucleic Acids Res, 2004, 32(22): e188.
[30]	Nandakumar P, Tin A, Grove ML, et al. MicroRNAs in the miR-17 and miR-15 families are downregulated in chronic kidney disease with hypertension [J]. PLoS One, 2017, 12(8): e0176734.
[31]	Klimczak D, Kuch M, Pilecki T, et al. Plasma microRNA-155-5p is increased among patients with chronic kidney disease and nocturnal hypertension [J]. J Am Soc Hypertens, 2017, 11(12): 831-841.
[32]	Stanković A, Kolaković A, Živković M, et al. Angiotensin receptor type 1 polymorphism A1166C is associated with altered AT1R and miR-155 expression in carotid plaque tissue and development of hypoechoic carotid plaques [J]. Atherosclerosis, 2016, 248: 132-139.
[33]	Ceolotto G, Papparella I, Bortoluzzi A, et al. Interplay between miR-155, AT1R A1166C polymorphism, and AT1R expression in young untreated hypertensives [J]. Am J Hypertens, 2011, 24(2): 241-246.
[34]	Diniz GP, Takano AP, Barreto-Chaves ML. MiRNA-208a and miRNA-208b are triggered in thyroid hormone-induced cardiac hypertrophy - role of type 1 angiotensin Ⅱ receptor (AT1R) on miRNA-208a/alpha-MHC modulation [J]. Mol Cell Endocrinol, 2013, 374(1-2): 117-124.
[35]	Huang BS, Wang H, Leenen FH. Enhanced sympathoexcitatory and pressor responses to central Na^＋ in Dahl salt-sensitive vs -resistant rats [J]. Am J Physiol Heart Circ Physiol, 2001, 281(5): H1881-H1889.
[36]	Nishimura M, Ohtsuka K, Nanbu A, et al. Benzamil blockade of brain Na^＋ channels averts Na(＋)-induced hypertension in rats [J]. Am J Physiol, 1998, 274 (3 Pt 2): R635-R644.
[37]	Huang BS, Leenen FH. Brain amiloride-sensitive Phe-Met-Arg-Phe-NH(2)-gated Na(＋) channels and Na(＋)-induced sympathoexcitation and hypertension [J]. Hypertension, 2002, 39(2 Pt 2): 557-561.
[38]	Liu D, Fernandez BO, Hamilton A, et al. UVA irradiation of human skin vasodilates arterial vasculature and lowers blood pressure independently of nitric oxide synthase [J]. J Invest Dermatol, 2014, 134(7): 1839-1846.
[39]	Opländer C, Volkmar CM, Paunel-Görgülü A, et al. Whole body UVA irradiation lowers systemic blood pressure by release of nitric oxide from intracutaneous photolabile nitric oxide derivates [J]. Circ Res, 2009, 105(10): 1031-1040.
[40]	Johnson RS, Titze J, Weller R. Cutaneous control of blood pressure [J]. Curr Opin Nephrol Hypertens, 2016, 25(1): 11-15.
[41]	Wimalawansa SJ. Vitamin D and cardiovascular diseases: causality [J]. J Steroid Biochem Mol Biol, 2018, 175: 29-43.
[42]	Mithal A, Wahl DA, Bonjour JP, et al. Global vitamin D status and determinants of hypovitaminosis D [J]. Osteoporos Int, 2009, 20(11): 1807-1820.
[43]	Ke L, Mason RS, Kariuki M, et al. Vitamin D status and hypertension: a review [J]. Integr Blood Press Control, 2015, 8: 13-35.
[44]	Karbach S, Croxford AL, Oelze M, et al. Interleukin 17 drives vascular inflammation, endothelial dysfunction, and arterial hypertension in psoriasis-like skin disease [J]. Arterioscler Thromb Vasc Biol, 2014, 34(12): 2658-2668.
[45]	Ji Y, Liu J, Wang Z, et al. PPARgamma agonist, rosiglitazone, regulates angiotensin Ⅱ-induced vascular inflammation through the TLR4-dependent signaling pathway [J]. Lab Invest, 2009, 89(8): 887-902.
[46]	Sugawara A, Uruno A, Matsuda K, et al. Effects of PPARgamma agonists against vascular and renal dysfunction [J]. Curr Mol Pharmacol, 2012, 5(2): 248-254.

Please choose a citation manager

Content to export